12th Nov 2014 14:24
LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that it has made a submission to the European Medicines Agency for a variation to the marketing authorisation for eltrombopag.
Glaxo is seeking an additional indication for the treatment of adult patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy.
Severe aplastic anaemia is a disorder where the bone marrow fails to make enough new blood cells. There are no approved therapies currently available in the EU for patients with this disorder.
Shares in Glaxo are trading up flat at 1,440.62 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline